Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer

LM. Peterson, BF. Kurland, F. Yan, AN. Jiresova, VK. Gadi, JM. Specht, JR. Gralow, EK. Schubert, JM. Link, KA. Krohn, JF. Eary, DA. Mankoff, HM. Linden

. 2021 ; 62 (2) : 184-190. [pub] 20200626

Language English Country United States

Document type Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21019345

Grant support
P01 CA042045 NCI NIH HHS - United States
T32 CA009515 NCI NIH HHS - United States
UL1 RR025014 NCRR NIH HHS - United States
P30 CA047904 NCI NIH HHS - United States

Histone deacetylase inhibitors (HDACIs) may overcome endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. We tested whether 18F-fluoroestradiol PET imaging would elucidate the pharmacodynamics of combination HDACIs and endocrine therapy. Methods: Patients with ER+/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer with prior clinical benefit from endocrine therapy but later progression on aromatase inhibitor (AI) therapy were given vorinostat (400 mg daily) sequentially or simultaneously with AI. 18F-fluoroestradiol PET and 18F-FDG PET scans were performed at baseline, week 2, and week 8. Results: Eight patients were treated sequentially, and then 15 simultaneously. Eight patients had stable disease at week 8, and 6 of these 8 patients had more than 6 mo of stable disease. Higher baseline 18F-fluoroestradiol uptake was associated with longer progression-free survival. 18F-fluoroestradiol uptake did not systematically increase with vorinostat exposure, indicating no change in regional ER estradiol binding, and 18F-FDG uptake did not show a significant decrease, as would have been expected with tumor regression. Conclusion: Simultaneous HDACIs and AI dosing in patients with cancer resistant to AI alone showed clinical benefit (6 or more months without progression) in 4 of 10 evaluable patients. Higher 18F-fluoroestradiol PET uptake identified patients likely to benefit from combination therapy, but vorinostat did not change ER expression at the level of detection of 18F-fluoroestradiol PET.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019345
003      
CZ-PrNML
005      
20210830100921.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.2967/jnumed.120.244459 $2 doi
035    __
$a (PubMed)32591490
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Peterson, Lanell M $u Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington
245    10
$a 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer / $c LM. Peterson, BF. Kurland, F. Yan, AN. Jiresova, VK. Gadi, JM. Specht, JR. Gralow, EK. Schubert, JM. Link, KA. Krohn, JF. Eary, DA. Mankoff, HM. Linden
520    9_
$a Histone deacetylase inhibitors (HDACIs) may overcome endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. We tested whether 18F-fluoroestradiol PET imaging would elucidate the pharmacodynamics of combination HDACIs and endocrine therapy. Methods: Patients with ER+/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer with prior clinical benefit from endocrine therapy but later progression on aromatase inhibitor (AI) therapy were given vorinostat (400 mg daily) sequentially or simultaneously with AI. 18F-fluoroestradiol PET and 18F-FDG PET scans were performed at baseline, week 2, and week 8. Results: Eight patients were treated sequentially, and then 15 simultaneously. Eight patients had stable disease at week 8, and 6 of these 8 patients had more than 6 mo of stable disease. Higher baseline 18F-fluoroestradiol uptake was associated with longer progression-free survival. 18F-fluoroestradiol uptake did not systematically increase with vorinostat exposure, indicating no change in regional ER estradiol binding, and 18F-FDG uptake did not show a significant decrease, as would have been expected with tumor regression. Conclusion: Simultaneous HDACIs and AI dosing in patients with cancer resistant to AI alone showed clinical benefit (6 or more months without progression) in 4 of 10 evaluable patients. Higher 18F-fluoroestradiol PET uptake identified patients likely to benefit from combination therapy, but vorinostat did not change ER expression at the level of detection of 18F-fluoroestradiol PET.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádory prsu $x diagnostické zobrazování $x metabolismus $x patologie $7 D001943
650    _2
$a estradiol $x analogy a deriváty $7 D004958
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a počítačové zpracování obrazu $7 D007091
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    12
$a pozitronová emisní tomografie $7 D049268
650    _2
$a receptor erbB-2 $x metabolismus $7 D018719
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a vorinostat $x farmakologie $7 D000077337
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kurland, Brenda F $u Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania
700    1_
$a Yan, Fengting $u Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington
700    1_
$a Jiresova, Alena Novakova- $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Gadi, Vijayakrishna K $u Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington $u Clinical Research and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
700    1_
$a Specht, Jennifer M $u Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington
700    1_
$a Gralow, Julie R $u Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington
700    1_
$a Schubert, Erin K $u Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
700    1_
$a Link, Jeanne M $u Department of Diagnostic Radiology, Oregon Health and Science University, Portland, Oregon; and
700    1_
$a Krohn, Kenneth A $u Department of Diagnostic Radiology, Oregon Health and Science University, Portland, Oregon; and
700    1_
$a Eary, Janet F $u Cancer Imaging Program, National Cancer Institute, Bethesda, Maryland
700    1_
$a Mankoff, David A $u Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
700    1_
$a Linden, Hannah M $u Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington hmlinden@uw.edu
773    0_
$w MED00010072 $t Journal of nuclear medicine : official publication, Society of Nuclear Medicine $x 1535-5667 $g Roč. 62, č. 2 (2021), s. 184-190
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32591490 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100921 $b ABA008
999    __
$a ok $b bmc $g 1690220 $s 1139791
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 62 $c 2 $d 184-190 $e 20200626 $i 1535-5667 $m The Journal of nuclear medicine $n J Nucl Med $x MED00010072
GRA    __
$a P01 CA042045 $p NCI NIH HHS $2 United States
GRA    __
$a T32 CA009515 $p NCI NIH HHS $2 United States
GRA    __
$a UL1 RR025014 $p NCRR NIH HHS $2 United States
GRA    __
$a P30 CA047904 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options